Trial Profile
Efficacy and safety of Apatinib in Small Cell Lung Cancer patients who failed from Two or More Lines of Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Oct 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 10 Oct 2018 New trial record
- 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer